KIT and chronic myelogenous leukemia, BCR-ABL1 positive: On the basis of our data, Figure 2 suggests that patients with tumours harbouring a ‘sensitive’ c-KIT genotype (KIT exon 11 mutations) are exposed to concentrations that are already near the top of the concentration–response curve (as was probably the case in our CML patients; see above).